Nature Biotechnology review timeline 2026

Manusights said in a 2026 review-timeline post that Nature Biotechnology takes about 25 days to desk reject a manuscript and about 2.9 months to reach a first decision after peer review. The figures, published on the company’s journal-guidance site, offer a current snapshot of how long authors may wait at one of biotechnology’s most selective titles. Manusights paired that timeline with a broader comparison of Nature and Scientific Reports, two journals in the Springer Nature orbit that apply very different editorial filters. The comparison framed timing as only one part of the submission decision, alongside selectivity, fit and the level of claimed significance. ### How long does Nature Biotechnology take before an author gets an answer? Manusights reported that Nature Biotechnology’s average time to desk rejection is about 25 days in 2026. The same post said the journal’s average time to first review decision is about 2.9 months, separating quick editorial triage from the slower path for papers that are sent to outside referees. The 25-day figure matters because it describes manuscripts that do not reach peer review. (manusights.com) The 2.9-month figure applies to papers that clear the initial editorial screen and move into the referee process, according to Manusights’ timeline page. ### Why are those two numbers so different? Nature Biotechnology sits inside a part of scientific publishing where editors screen heavily before review. (manusights.com) Manusights’ broader guide to Nature submissions said journal fit is a common reason for early rejection, and its Nature Biotechnology materials describe the title as highly selective and focused on technology with clear scientific and societal impact. A separate Manusights page on submission process said the company built its timeline guidance from journal instructions, editorial-policy pages, Nature Portfolio submission flow and its own review-pattern analysis. That means the figures are presented as an aggregate estimate rather than a guarantee for any individual paper. ### What does Manusights compare Nature Biotechnology against? (manusights.com) Manusights used Scientific Reports as the clearest contrast case in a separate comparison article on Nature versus Scientific Reports. That piece said Nature publishes about 50 research papers per issue, while Scientific Reports publishes thousands of papers per year. Scientific Reports operates with a broader acceptance threshold centered on technical soundness rather than breakthrough-level novelty, Manusights said. (manusights.com) In the same comparison, Manusights described Nature as a venue for papers it called “field-shifting” and estimated Nature’s acceptance rate at about 6%, versus about 57% for Scientific Reports. ### Is this a Nature Biotechnology policy change? (manusights.com) The June 2026 material does not describe a new policy announcement from Nature Biotechnology or from Springer Nature. The Manusights posts are presented as journal-guidance and benchmarking material for authors deciding where to submit, not as a statement by the publisher about a changed editorial rule. The source set also does not show a new Nature-wide peer-review reform tied to these numbers. (manusights.com) Instead, the pages present a practical estimate of current review timing and a comparison of how different journals in the market handle selectivity and volume. ### What should authors watch next? Nature Biotechnology’s next step for any individual manuscript still depends on whether editors send it to referees after the initial screen. (manusights.com) Manusights’ related 2026 guides on submission process, “under consideration” status and peer-review timelines provide the next reference points for authors tracking movement after submission. Manusights’ comparison pages remain the most direct place to check the current estimates cited here, including the Nature Biotechnology review-time entry and the Nature-versus-Scientific Reports guide published in late May 2026. (manusights.com 1) (manusights.com 2)